Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05576350 · ClinicalTrials.gov registry record · NA

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

A NA study of HIV Infections and Alcohol Use Disorder, sponsored by University of Kentucky.

Recruiting
Registry status
NA
Development phase
405
Enrollment target
2
Study locations

NCT05576350: Recruiting NA study of HIV Infections and Alcohol Use Disorder, sponsored by University of Kentucky.

NCT05576350 is a NA study of HIV Infections and Alcohol Use Disorder that is actively recruiting participants, run by University of Kentucky. The registered enrollment target is 405 participants, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05576350, a NA study of HIV Infections and Alcohol Use Disorder, is actively recruiting participants, sponsored by University of Kentucky.

RECRUITING
Registry status
NA
Development phase
405 participants
Enrollment target
2
Study locations

Study Summary

Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use. A mobile app has been developed that uses GPS tracking to determine when individuals visit "risky" places and then delivers a survey asking what behaviors they engaged in while at the location. The goal of the proposed study is to use this app to enhance the Tracking and Reducing Alcohol Consumption (TRAC) intervention by delivering messages that encourage participants to employ strategies discussed during TRAC sessions when arriving at risky places. When they leave these places, they will complete a survey and breathalyzer reading in order to collect event-level self-report and biological data on alcohol use and HIV risk. If their breathalyzer result indicates alcohol use, they will receive harm reduction messaging. It is expected that combining TRAC with EMI ("TRAC-ER") will increase effectiveness by reinforcing topics discussed during these sessions, providing in-the-moment messaging to address triggers, and collecting real-time alcohol use data.

Primary Outcome

Number of days in which alcohol was consumed based on breathalyzer readings greater than 0.00

Interventions

  • BEHAVIORAL Smartphone Based Alcohol Monitoring (SAM)
  • BEHAVIORAL Tracking and Reducing Alcohol Consumption (TRAC)
  • BEHAVIORAL TRAC-ER

Study Locations (2)

Connecticut

  • Yale University - New Haven

Kentucky

  • University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 405 participants
Start Date 2024-12-09
Est. Completion 2027-05
Phase NA
University of Kentucky

54 total trials

What NCT05576350 shows while recruiting

NCT05576350 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 445-participant average among 542 other HIV Infections trials with a reported enrollment target.

The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Smartphone Based Alcohol Monitoring (SAM) is the first listed.

NCT05576350 reports a single indexed study location in Connecticut, Kentucky.

Frequently Asked Questions

What is clinical trial NCT05576350 about?

NCT05576350 is a clinical study titled "TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk". Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinki...

What is the current status of trial NCT05576350?

This trial is currently recruiting. It is a NA study. The enrollment target is 405 participants. The study started on 2024-12-09. Estimated completion is 2027-05.

What conditions does trial NCT05576350 study?

This clinical trial studies the following conditions: HIV Infections, Alcohol Use Disorder, Risk Behavior.

What interventions are being tested in trial NCT05576350?

The interventions under investigation include: Smartphone Based Alcohol Monitoring (SAM) (BEHAVIORAL), Tracking and Reducing Alcohol Consumption (TRAC) (BEHAVIORAL), TRAC-ER (BEHAVIORAL).

Who is sponsoring clinical trial NCT05576350?

This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05576350 being conducted?

This trial has 2 study locations across Connecticut, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05576350's enrollment target sits among peer trials

405 78th of 542 higher than 464 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07066657 · 405 participants · Phase 1

    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  • NCT06223360 · 406 participants · Phase 2

    A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

  • NCT06411769 · 406 participants · NA

    Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas

  • NCT06585787 · 406 participants · Phase 3

    A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05576350, the US trial registry maintained by the National Library of Medicine. NCT05576350 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.